by According to Precedence Research, during the forecast period of 2022 to 2030, the global geriatric medicines market is estimated to develop at a compound annual growth rate (CAGR) of 6.8%. The global geriatric medicines market was valued at USD 835.53 billion in 2021, and it is predicted to exceed USD 1,423.6 billion by 2030. The study investigates several elements and their consequences on the growth of the geriatric medicines market.
Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/1690
This report focuses on geriatric medicines market volume and value at the global level, regional level and company level. From a global perspective, this report represents overall geriatric medicines market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Middle East & Africa, Latin America, etc.
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
In-Depth Analysis on Competitive Landscape
The report sheds light on leading manufacturers of geriatric medicines, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in the production of geriatric medicines has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the geriatric medicines market.
Some of the prominent players in the geriatric medicines market include:
- GlaxoSmithKline PLC
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Bristol-Myers Squibb Company
- Boehringer Ingelheim GmbH
- Merck & Company Inc.
- Abbott Laboratories Inc.
- Eli Lilly & Company
- AstraZeneca PLC
Ask Here For More Customization Study@ https://www.precedenceresearch.com/customization/1690
Segments Covered in the Report
By Therapeutics
- Analgesic
- Antihypertensive
- Statins
- Antidiabetic
- PPI
- Anticoagulant
- Antipsychotic
- Others
By Condition
- Cardiovascular
- Arthritis
- Neurological
- Cancer
- Osteoporosis
- Respiratory
- Others
By Distribution Channels
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
By Route of Administration
- Oral
- Parenteral
- Others
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Some of the important ones are:
- What can be the best investment choices for venturing into new product and service lines?
- What value propositions should businesses aim at while making new research and development funding?
- Which regulations will be most helpful for stakeholders to boost their supply chain network?
- Which regions might see the demand maturing in certain segments in near future?
- What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
- Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
- Which government regulations might challenge the status of key regional markets?
- How will the emerging political and economic scenario affect opportunities in key growth areas?
- What are some of the value-grab opportunities in various segments?
- What will be the barrier to entry for new players in the market?
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Geriatric Medicines Market
5.1. COVID-19 Landscape: Geriatric Medicines Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Geriatric Medicines Market, By Therapeutics
8.1. Geriatric Medicines Market, by Therapeutics Type, 2022-2030
8.1.1. Analgesic
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Antihypertensive
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Statins
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Antidiabetic
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. PPI
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Anticoagulant
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Antipsychotic
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Others
8.1.8.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Geriatric Medicines Market, By Condition
9.1. Geriatric Medicines Market, by Condition, 2022-2030
9.1.1. Cardiovascular
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Arthritis
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Neurological
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Respiratory
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Osteoporosis
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Cancer
9.1.6.1. Market Revenue and Forecast (2017-2030)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Geriatric Medicines Market, By Distribution Channels
10.1. Geriatric Medicines Market, by Distribution Channels Type, 2022-2030
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Online Pharmacies
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Retail Pharmacies
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Geriatric Medicines Market, By Route of Administration
11.1. Geriatric Medicines Market, by Route of Administration Type, 2022-2030
11.1.1. Oral
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Parenteral
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Geriatric Medicines Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.1.2. Market Revenue and Forecast, by Condition (2017-2030)
12.1.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.1.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Condition (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Condition (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.2.2. Market Revenue and Forecast, by Condition (2017-2030)
12.2.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.2.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Condition (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Condition (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Condition (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Condition (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.3.2. Market Revenue and Forecast, by Condition (2017-2030)
12.3.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.3.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Condition (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Condition (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Condition (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Condition (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.4.2. Market Revenue and Forecast, by Condition (2017-2030)
12.4.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.4.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Condition (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Condition (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Condition (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Condition (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.5.2. Market Revenue and Forecast, by Condition (2017-2030)
12.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Condition (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Condition (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
Chapter 13. Company Profiles
13.1. GlaxoSmithKline PLC
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Novartis AG
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Pfizer Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Sanofi S.A.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Bristol-Myers Squibb Company
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Boehringer Ingelheim GmbH
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Merck & Company Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Abbott Laboratories Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Eli Lilly & Company
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. AstraZeneca PLC
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/1690
About Us
Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.
From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
